Hemostats Market to be Worth $5.32 Billion by 2031

Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled ‘Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User - Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the hemostats market is projected to reach $5.32 billion by 2031, at a CAGR of 6.9% during the forecast period. The growth of this market is driven by the increasing volume of surgical procedures performed, high research and development in surgical devices sector, increasing rate of accidents, rise in number of cesarean deliveries, fatal injuries, and organ transplantation, increased R&D activities by government organizations and the private sector, rising government healthcare spending, and growing adoption of minimally invasive surgical procedures. Additionally, the increasing need to control blood loss by using advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to offer significant market growth opportunities.

However, the allergic reactions caused by the hemostatic material restrain the growth of this market. Additionally, the high manufacturing cost for hemostats poses a significant challenge to the market's growth.

Key Players

The key players operating in the hemostats market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).

Hemostats Market: Future Outlook

The hemostats market is segmented based on Type (Absorbable Hemostats [Mechanical or Passive Agents {Gelatin-based Hemostat, Collagen Hemostat, Oxidized Regenerated Cellulose Hemostat}, Flowable and Active Agents {Thrombin-based Hemostat, Combination Hemostat}, Other Absorbable Hemostat], Non-absorbable Hemostats [Fibrin Sealants, Synthetic Sealants, Hemostatic Gauze, Hemostatic Forceps]), Application (Surgery [Orthopedic Surgery, General Surgery, Gynecology Surgery, Cardiovascular Surgery, Neurosurgery, Plastic Surgery, Other Surgeries], Dental Treatments, Traumatic Injury), Form (Sponges and Dressings, Sheets and Pads, Powder, Matrix and Gel, and Tools).

The hemostats market is further segmented based on End User (Hospitals & Clinics, Ambulatory Surgical Centers, Nursing Homes) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.

Based on the product, the hemostats market is segmented into absorbable hemostats and non-absorbable hemostats. In 2024, the absorbable hemostats segment is expected to account for the larger share of the hemostats market. The large market share of this segment is attributed to the advantages offered by absorbable hemostats such as they are utilized to stop mild bleeding, rapid embolization, and aid wound hemostasis. Additionally, their availability in versatile forms such as powder, sheets, sponges, and matrix and gels have contributed to their larger adoption by various end users.

Based on the application, the hemostats market is segmented into surgery, dental treatments, and traumatic injury. In 2024, the surgery segment is expected to account for the largest share of the hemostats market. The large market share of this segment is attributed to factors such as increasing number of surgeries, the rise in the use of hemostats for emergency wound care, and the advantages of hemostats for effective bleeding control during surgery.

Based on the form, the hemostats market is segmented into sponges and dressings, sheets and pads, powder, matrix and gel, and tools. In 2024, the matrix and gel segment is expected to account for the largest share of the hemostats market. This segment is also expected to register the highest growth during the forecast period. The advantages associated with matrix and gel hemostats, such as cost-effectiveness, easy application, and biocompatibility, contribute to the largest share of the segment. Additionally, the use of matrix and gel hemostats in bleeding control when conventional procedures are not effective is further driving the market growth of this segment.

Based on end user, the hemostats market is segmented into hospitals & clinics, ambulatory surgical centers, and nursing homes. In 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostats market. The recurrent use of hemostats in surgeries to prevent/stop bleeding from the bleeding site, provide clinical performance and economic efficiencies for intraoperative bleeding management, large volume of surgeries conducted, and traumatic injuries are treated at hospitals, and availability of favorable reimbursement policies are some of the major factors contributing to the growth of this segment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa. In 2023, North America is expected to account for the largest share of the hemostats market, followed by Europe and Asia-Pacific. Furthermore, in 2023, the U.S. is expected to be the largest market shareholder in North America. The U.S.’s major market share is mainly attributed to the presence of key players in the U.S. holding established distribution channels, favorable healthcare policies and reimbursement scenarios, willingness to spend on advanced hemostatic solutions, and established healthcare infrastructure in the region.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5833

Key questions answered in the report:

Which are the high-growth market segments in terms of type, application, form, end user, and region/country?
What was the historical market size for hemostats across the globe?
What are the market forecasts and estimates for 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the global hemostats market?
Who are the major players in the global hemostats market?
What is the competitive landscape like, and who are the market leaders in the global hemostats market?
What are the recent developments in the hemostats market?
What strategies are adopted by the major players in the hemostats market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research